Biocon Limited, Asia’s premier bio-pharmaceuticals company, and JDRF, the leading global organisation funding Type 1 Diabetes (T1D) Research and Advocacy world-wide, have entered into partnership for a global study on oral insulin drug for treatment with TID.

Insulin Tregopil, a first-in-class oral insulin molecule being developed by Biocon, is one of the most advanced programmes in the global oral insulin space, a Biocon release said here today. Biocon proposes to conduct an open label study to evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), safety and tolerability of multiple ascending doses of Insulin Tregopil and to compare the PK, PD and safety of the optimal dose regimen of Insulin Tregopil with therapeutic doses of Insulin Aspart in individuals with T1D.

Biocon CMD Kiran Mazumdar Shaw said "We believe Insulin Tregopil can make a significant difference to the diabetes management paradigm for both type 1 and type 2 diabetes and welcome JDRF's support in advancing this unique oral insulin molecule through the clinic for type 1 diabetes. With this proposed clinical study, we hope to build on the extremely promising data that we have generated so far through previous human trials with Tregopil. We are committed to addressing the huge unmet need of people with diabetes by providing the medical community an alternate treatment for postprandial hyperglycemia." JDRF, Director, Translational Development, Esther Latres said "JDRF has been supportive of oral insulin studies to help people with type 1 diabetes better manage their glucose levels with less need for injected insulin."